Ezetimibe/simvastatin combination not found to increase cancer risk, mortality
the ONA take:
According to a new study published in the American Journal of Cardiology, researchers have found that treatment with ezetimibe/simvastatin (Vytorin) is not linked with an elevated risk for developing cancer or an increased risk of cancer-related mortality.
Researchers identified 1,359 eligible patients for follow-up from the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study so that they could investigate new incidences of cancer and total mortality over 21 months following the end of the SEAS trial. Of the 1,359 patients, 1,194 had no history of cancer cancer.
In that portion of patients, 12 patients who received ezetimibe/simvastatin had developed cancer and 22 patients that received placebo developed cancer in the 21-month follow-up (HR 0.55, 95% CI 0.27 - 1.11). During the same period, 43 patients who received ezetimibe/simvastatin and 33 who received placebo died (HR 1.29, 95% CI 0.82 - 2.03).
Results suggest that treatment with the lipid-lowering combination was not linked with an increased risk for developing cancer or dying from cancer during the 21-month follow-up to the SEAS trial. Numerous authors reported financial disclosures with Merck & Co., the manufacturer of Vytorin.
Ezetimibe/simvastatin (Vytorin) is not linked with an elevated risk for developing cancer.
Sign Up for Free e-newsletters
- Is Radioimmunotherapy a Path Forward for Melanoma?
- FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma
- New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab
- Intensive Chemotherapy May Not Be Effective in MDS or AML After MDS
- ASCO Endorses SIO Guideline for Integrative Therapies in Breast Cancer
- Seeking Reliable Information on Herbal Products
- NCCIH HerbList App Launched to Provide Information on Herbal Products
- Metformin Use May Improve Survival Outcomes in Bladder Cancer
- Higher Vitamin D Levels Associated With Lower Breast Cancer Risk
- Nurse-Led Program Improves Health, Financial Outcomes in Outpatient Chemotherapy
- Disparities Remain in Prevalence of Cancer Screening Tests
- Hope, Gratitude, and Spirituality: What They Mean to Cancer Patients
- FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma
- 8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers
- Combined Digital Screening Best for Detecting Breast Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|